Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Jefferies Financial
JEF
HK Stock MarketDetailed Quotes
02410 TYK MEDICINES-B
- 34.350
- +5.450+18.86%
Market Closed May 2 16:08 CST
12.74BMarket Cap-30.48P/E (TTM)
34.350High27.900Low3.25MVolume28.600Open28.900Pre Close101.26MTurnover0.89%Turnover RatioLossP/E (Static)370.84MShares56.55052wk High25.15P/B12.58BFloat Cap12.86052wk Low--Dividend TTM366.23MShs Float56.550Historical High--Dividend LFY22.32%Amplitude12.860Historical Low31.194Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
About TYK MEDICINES-B Company
Tongyuankang Pharmaceutical was founded in November 2017, established a 30,000 square meter new drug research and development center in Changxing Life Science Park in Huzhou, Zhejiang, then established the company's administrative headquarters, clinical medicine department and business development department in Shanghai, set up a small molecule drug screening platform in Zhengzhou, and is building new drug formulation plants in Changxing and Shanghai's Songjiang district. It is one of the few innovative biomedical high-tech companies in China with drug development and production capabilities.
Company Profile
Symbol02410
Company NameTYK MEDICINES-B
ISINCNE100006L34
Listing DateAug 20, 2024
Issue Price12.10
Shares Offered47.88M share(s)
FoundedNov 2, 2017
Registered AddressChina
Chairmanyusheng wu
Secretaryyongyijiangmingyu huang
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeRoom 1403-2, 14th Floor, Block A, Changxing World Trade Center, No. 1278 Mingzhu Road, Changxing Economic Development Zone, Huzhou, Zhejiang, China
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees153
MarketHong Kong motherboard
Phone(021)61676766;(0572)6088932;(0371)60296579
Fax(021)60107317
EmailBD@tykmedicines.com;investors@tykmedicines.com
Websitehttp://www.tykmedicines.com
Business Zhejiang Tongyuankang Pharmaceutical Co., Ltd. is a Chinese company dedicated to developing and commercializing pharmaceutical products. The company focuses on small molecule drug development, and its main products include TY-9591, TY-302, and TY-2136. TY-9591 is a third-generation EGFR-TKI with anti-tumor effects on EGFR mutations. TY-302 is a potent and selective oral CDK4/6 inhibitor developed to treat advanced solid tumors such as breast cancer and prostate cancer. TY-2136b is an independently developed and orally administered ROS1/NTRK inhibitor for the treatment of solid tumors.
Company Executives
- Name
- Position
- Salary
- yusheng wu
- Chairman, President, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members
- --
- mingyu jiang
- VP, Executive Director, Joint Company Secretary, Board Secretary, Authorized Representative
- --
- jun li
- Non-executive Directors, Audit Committee Members
- --
- hong gu
- Non-executive Directors
- --
- xiaoying meng
- Non-executive Directors
- --
- chao he
- Non-executive Directors
- --
- senquan zhang
- Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members, Nomination Committee Members
- --
- yuting leng
- Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
- --
- wenqing xu
- Independent Non-Executive Director
- --
- xiuhua shen
- Independent Non-Executive Director
- --
- chengshan niu
- Senior Director of Pharmaceutical Chemistry, Chairman of the Supervisory Board, Employee Representative Supervisor
- --
- apeng liang
- Director of Pharmacology, Employee Representative Supervisor
- --
- jing shang
- Shareholders' Representatives and Supervisors
- --
- shaoqing chen
- Senior Vice President of Pharmaceuticals
- --
- xiugui chen
- Senior Vice President of Clinical Registries
- --
- yongyi huang
- Joint Company Secretary, Authorized Representative
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts